stethoscope

Join our network and find credentialing information.

Log in to Availity Essentials™ to access patient benefits, claims information and more.

Find tools and materials to support doing business with us.

Learn more about research and trends that impact your practice.

Find self-service info and phone numbers and update your provider data.

Review prior authorization lists for services, medications and submission guidance.

Prior authorization submission information

Professionally administered drugs prior authorization

Find appeals guidelines and payment policy information.

Learn how to submit claims and find coding guidance.

Find policies for procedures, devices and medications.

Review guidelines and health programs to support your patients and practice.

Find dental benefits, tools and resources.

Prior authorization for professionally administered drugs 

Locate state-specific resources for Humana Healthy Horizons® (Medicaid).

compass

Shop plans, learn about Medicare and explore member resources.

Search for in-network medical, vision, dental and pharmacy providers.

GLP-1 Medically Accepted Indication Update

A couple researching a prescription online

Diagnosis requirements for glucagon-like peptide-1 (GLP-1) agonists:

 Effective June 1, 2023, Humana will require pharmacies to enter a diagnosis code for a medically accepted indication supplied by the prescriber when processing a prescription claim for a GLP-1 receptor agonist for Humana-covered patients. Beginning on the above date, please include the diagnosis on the GLP-1 prescription to minimize delays in dispensing the medication.

GLP-1 agonists are indicated for type 2 diabetes treatment. They also have shown benefits for obesity and weight management treatment. However, weight loss is excluded from coverage on Humana commercial and MAPD/PDP plans, so GLP-1 agonists will not be covered for this use.

GLP-1 agonists currently approved by the U.S. Food and Drug Administration (FDA) for type 2 diabetes mellitus treatment as an adjunct to diet and exercise include:

 Adlyxin® (lixisenatide)

Bydureon® (exenatide)

Byetta® (exenatide)

Mounjaro® (tirzepatide)

Ozempic® (semaglutide)

Rybelsus® (semaglutide)

Trulicity® (dulaglutide)

Victoza® (liraglutide)


GLP-1 agonists currently approved by the FDA for obesity and chronic weight management treatment as an adjunct to a reduced-calorie diet and increased physical activity include:

Saxenda® (liraglutide)

Wegovy® (semaglutide)


Prescribers with questions regarding this change can call 800-555-CLIN (2546), Monday ─ Friday, 8 a.m. ─ 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991, Monday ─ Friday, 8 a.m. ─ 8 p.m., Eastern time.

  Please see the table below for a list of common International Classification of Diseases, 10th Revision (ICD-10) codes corresponding to the conditions outlined in this communication.

 ICD-10-CM created by the National Center for Health Statistics under authorization by the World Health Organization (WHO). WHO is the copyright holder.

The American Academy of Professional Coders.



Drug recall notice for Nature-Throid and WP Thyroid tablets

Drug recall notice for Belviq, Belviq XR (lorcaserin)

Drug recall notice for NP Thyroid tablets

Drug recall notice for Taro Pharmaceuticals phenytoin oral suspension

Formulary changes for generic Ventolin HFA

Impact of ongoing angiotensin II receptor blocker drug recalls

References:

Pharmacy news